- Prothena (NASDAQ:PRTA) announces that it and licensee Roche (OTCQX:RHHBY) will advance prasinezumab into a Phase 2b study in patients with early Parkinson's disease (PD). It will earn a $60M milestone payment when the first participant is dosed.
- In April, Roche announced that Part 1 of a Phase 2 study, PASADENA, evaluating the candidate in the same population of PD sufferers failed to achieve the primary efficacy endpoint. The extension phase (Part 2) is ongoing.
- Prasinezumab is a humanized monoclonal antibody that binds to a protein called alpha-synuclein that is found primarily in brain tissue and linked to PD via its interference with brain cell signaling in its aberrant forms.
- https://seekingalpha.com/news/3623955-roche-to-advance-development-of-parkinsons-candidate-despite-underwhelming-data
Tuesday, October 20, 2020
Roche to advance development of Parkinson's candidate despite underwhelming data
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.